---
document_datetime: 2025-12-02 06:20:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/qoyvolma.html
document_name: qoyvolma.html
version: success
processing_time: 0.1109554
conversion_datetime: 2025-12-25 06:26:36.058771
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Qoyvolma

[RSS](/en/individual-human-medicine.xml/256954)

##### Authorised

This medicine is authorised for use in the European Union

ustekinumab Medicine Human Authorised

Qoyvolma

## Qoyvolma

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Qoyvolma](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Qoyvolma is a medicine used to treat:

- moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is used in adults and children above the age of 6 years whose condition has not improved with, or who cannot use, other systemic (whole-body) psoriasis treatments, such as ciclosporin, methotrexate or PUVA (psoralen and ultraviolet A). PUVA is a type of treatment where the patient receives a medicine called psoralen, before being exposed to ultraviolet light;
- active psoriatic arthritis (inflammation of the joints associated with psoriasis) in adults, when the condition has not improved enough with other treatments called disease-modifying anti-rheumatic drugs (DMARDs). Qoyvolma may be used alone or combined with methotrexate (a DMARD);
- moderately to severely active Crohn's disease (a disease-causing inflammation of the gut) in adults and children weighing at least 40 kg whose condition has not improved enough with other treatments or who cannot receive such treatments;
- moderately to severely active ulcerative colitis (inflammation of the large intestine causing ulceration and bleeding) in adults whose condition has not improved enough with other treatments for ulcerative colitis or who cannot receive such treatments.

Qoyvolma contains the active substance ustekinumab and is a biological medicine. It is a 'biosimilar medicine'; this means that Qoyvolma is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Qoyvolma is Stelara. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines) .

Expand section

Collapse section

## How is Qoyvolma used?

Qoyvolma can only be obtained with a prescription and should be given under the supervision of a doctor who has experience in diagnosing and treating the diseases that Qoyvolma is used for.

Qoyvoma is given as an infusion (drip) into a vein or an injection under the skin with a pre-filled syringe.

In plaque psoriasis and psoriatic arthritis, Qoyvolma is injected under the skin. The first injection is followed by another injection 4 weeks later. After that, one injection is given every 12 weeks.

In Crohn's disease and ulcerative colitis, treatment is started as an infusion into a vein lasting at least 1 hour. Eight weeks after the first infusion, Qoyvolma is given as an injection under the skin. Patients then continue with Qoyvolma injected under the skin every 8 or 12 weeks depending on how well the treatment is working.

Patients or their caregivers may inject Qoyvolma once they have been trained, if their doctor thinks that this is appropriate.

For more information about using Qoyvolma, see the package leaflet or contact your doctor or pharmacist.

## How does Qoyvolma work?

The active substance in Qoyvolma, ustekinumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific target in the body. Ustekinumab attaches to 2 messenger molecules in the immune system called interleukin 12 and interleukin 23. Both are involved in inflammation and other processes that are important in psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. By attaching to them and blocking their activity, ustekinumab reduces the activity of the immune system and the symptoms of the diseases.

## What benefits of Qoyvolma have been shown in studies?

Laboratory studies comparing Qoyvolma with Stelara have shown that the active substance in Qoyvolma is highly similar to that in Stelara in terms of structure, purity and biological activity. Studies have also shown that giving Qoyvolma produces similar levels of the active substance in the body to those seen with Stelara.

In addition, a study in 509 patients with moderate to severe plaque psoriasis showed that Qoyvolma is as effective as Stelara in improving symptoms of the disease. After 12 weeks of treatment, patients' symptom scores improved similarly with both medicines.

Because Qoyvolma is a biosimilar medicine, the studies on the effectiveness of ustekinumab carried out with Stelara do not all need to be repeated for Qoyvolma.

## What are the risks associated with Qoyvolma?

The safety of Qoyvolma has been evaluated and, based on all studies carried out, its side effects are considered comparable to those of Stelara.

For the complete list of side effects and restrictions of Qoyvolma, see the package leaflet.

The most common side effects with ustekinumab (which may affect more than 1 in 20 people) include headache and nasopharyngitis (inflammation of the nose and throat). The most serious side effect reported with ustekinumab include serious hypersensitivity (allergic reaction).

Qoyvolma must not be used in patients who have an active infection that the doctor considers important.

## Why is Qoyvolma authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Qoyvolma has a highly similar structure, purity and biological activity to Stelara and is distributed in the body in the same way. In addition, a study in plaque psoriasis has shown that Qoyvolma and Stelara are equivalent in terms of safety and effectiveness in this condition.

All these data were considered sufficient to conclude that Qoyvolma will have the same effects as Stelara in its authorised uses. Therefore, the Agency's view was that, as for Stelara, the benefits of Qoyvolma outweigh its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Qoyvolma?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Qoyvolma have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Qoyvolma are continuously monitored. Suspected side effects reported with Qoyvolma are carefully evaluated and any necessary action taken to protect patients.

## Other information about Qoyvolma

Qoyvolma received a marketing authorisation valid throughout the EU on 02 June 2025.

Qoyvolma : EPAR - Medicine overview

English (EN) (135.42 KB - PDF)

**First published:** 10/06/2025

**Last updated:** 17/10/2025

[View](/en/documents/overview/qoyvolma-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-558)

български (BG) (163.22 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/bg/documents/overview/qoyvolma-epar-medicine-overview_bg.pdf)

español (ES) (134.91 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/es/documents/overview/qoyvolma-epar-medicine-overview_es.pdf)

čeština (CS) (160.83 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/cs/documents/overview/qoyvolma-epar-medicine-overview_cs.pdf)

dansk (DA) (135.58 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/da/documents/overview/qoyvolma-epar-medicine-overview_da.pdf)

Deutsch (DE) (139.86 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/de/documents/overview/qoyvolma-epar-medicine-overview_de.pdf)

eesti keel (ET) (132.78 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/et/documents/overview/qoyvolma-epar-medicine-overview_et.pdf)

ελληνικά (EL) (162.48 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/el/documents/overview/qoyvolma-epar-medicine-overview_el.pdf)

français (FR) (136.29 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/fr/documents/overview/qoyvolma-epar-medicine-overview_fr.pdf)

hrvatski (HR) (157.97 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/hr/documents/overview/qoyvolma-epar-medicine-overview_hr.pdf)

italiano (IT) (134.07 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/it/documents/overview/qoyvolma-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (165.17 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/lv/documents/overview/qoyvolma-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (157.55 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/lt/documents/overview/qoyvolma-epar-medicine-overview_lt.pdf)

magyar (HU) (158.71 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/hu/documents/overview/qoyvolma-epar-medicine-overview_hu.pdf)

Malti (MT) (160.99 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/mt/documents/overview/qoyvolma-epar-medicine-overview_mt.pdf)

Nederlands (NL) (136.88 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/nl/documents/overview/qoyvolma-epar-medicine-overview_nl.pdf)

polski (PL) (162.66 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/pl/documents/overview/qoyvolma-epar-medicine-overview_pl.pdf)

português (PT) (135.93 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/pt/documents/overview/qoyvolma-epar-medicine-overview_pt.pdf)

română (RO) (155.25 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/ro/documents/overview/qoyvolma-epar-medicine-overview_ro.pdf)

slovenčina (SK) (159.94 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/sk/documents/overview/qoyvolma-epar-medicine-overview_sk.pdf)

slovenščina (SL) (156.86 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/sl/documents/overview/qoyvolma-epar-medicine-overview_sl.pdf)

Suomi (FI) (132.35 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/fi/documents/overview/qoyvolma-epar-medicine-overview_fi.pdf)

svenska (SV) (133.63 KB - PDF)

**First published:**

10/06/2025

**Last updated:**

17/10/2025

[View](/sv/documents/overview/qoyvolma-epar-medicine-overview_sv.pdf)

Qoyvolma : EPAR - Risk management plan

English (EN) (1.43 MB - PDF)

**First published:** 10/06/2025

**Last updated:** 09/09/2025

[View](/en/documents/rmp/qoyvolma-epar-risk-management-plan_en.pdf)

## Product information

Qoyvolma : EPAR - Product information

English (EN) (1.82 MB - PDF)

**First published:** 10/06/2025

**Last updated:** 09/09/2025

[View](/en/documents/product-information/qoyvolma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-673)

български (BG) (1.98 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/bg/documents/product-information/qoyvolma-epar-product-information_bg.pdf)

español (ES) (1.77 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/es/documents/product-information/qoyvolma-epar-product-information_es.pdf)

čeština (CS) (2.05 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/cs/documents/product-information/qoyvolma-epar-product-information_cs.pdf)

dansk (DA) (1.83 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/da/documents/product-information/qoyvolma-epar-product-information_da.pdf)

Deutsch (DE) (1.71 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/de/documents/product-information/qoyvolma-epar-product-information_de.pdf)

eesti keel (ET) (1.78 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/et/documents/product-information/qoyvolma-epar-product-information_et.pdf)

ελληνικά (EL) (2 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/el/documents/product-information/qoyvolma-epar-product-information_el.pdf)

français (FR) (1.79 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/fr/documents/product-information/qoyvolma-epar-product-information_fr.pdf)

hrvatski (HR) (2.04 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/hr/documents/product-information/qoyvolma-epar-product-information_hr.pdf)

íslenska (IS) (2.05 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/is/documents/product-information/qoyvolma-epar-product-information_is.pdf)

italiano (IT) (1.76 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/it/documents/product-information/qoyvolma-epar-product-information_it.pdf)

latviešu valoda (LV) (1.81 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/lv/documents/product-information/qoyvolma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.91 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/lt/documents/product-information/qoyvolma-epar-product-information_lt.pdf)

magyar (HU) (1.98 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/hu/documents/product-information/qoyvolma-epar-product-information_hu.pdf)

Malti (MT) (1.93 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/mt/documents/product-information/qoyvolma-epar-product-information_mt.pdf)

Nederlands (NL) (1.9 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/nl/documents/product-information/qoyvolma-epar-product-information_nl.pdf)

norsk (NO) (1.81 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/no/documents/product-information/qoyvolma-epar-product-information_no.pdf)

polski (PL) (1.82 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/pl/documents/product-information/qoyvolma-epar-product-information_pl.pdf)

português (PT) (1.8 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/pt/documents/product-information/qoyvolma-epar-product-information_pt.pdf)

română (RO) (1.84 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/ro/documents/product-information/qoyvolma-epar-product-information_ro.pdf)

slovenčina (SK) (2.05 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/sk/documents/product-information/qoyvolma-epar-product-information_sk.pdf)

slovenščina (SL) (1.87 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/sl/documents/product-information/qoyvolma-epar-product-information_sl.pdf)

Suomi (FI) (1.92 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/fi/documents/product-information/qoyvolma-epar-product-information_fi.pdf)

svenska (SV) (1.84 MB - PDF)

**First published:**

10/06/2025

**Last updated:**

09/09/2025

[View](/sv/documents/product-information/qoyvolma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000280926 05/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Qoyvolma : EPAR - All authorised presentations

English (EN) (62.8 KB - PDF)

**First published:** 10/06/2025

[View](/en/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-12)

български (BG) (67.9 KB - PDF)

**First published:**

10/06/2025

[View](/bg/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_bg.pdf)

español (ES) (62.6 KB - PDF)

**First published:**

10/06/2025

[View](/es/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (71.59 KB - PDF)

**First published:**

10/06/2025

[View](/cs/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (65.73 KB - PDF)

**First published:**

10/06/2025

[View](/da/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (65.8 KB - PDF)

**First published:**

10/06/2025

[View](/de/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (59.87 KB - PDF)

**First published:**

10/06/2025

[View](/et/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (64.25 KB - PDF)

**First published:**

10/06/2025

[View](/el/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_el.pdf)

français (FR) (62.66 KB - PDF)

**First published:**

10/06/2025

[View](/fr/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (62.23 KB - PDF)

**First published:**

10/06/2025

[View](/hr/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (64.64 KB - PDF)

**First published:**

10/06/2025

[View](/is/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (62.07 KB - PDF)

**First published:**

10/06/2025

[View](/it/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (64.62 KB - PDF)

**First published:**

10/06/2025

[View](/lv/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.49 KB - PDF)

**First published:**

10/06/2025

[View](/lt/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (60.9 KB - PDF)

**First published:**

10/06/2025

[View](/hu/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (61.55 KB - PDF)

**First published:**

10/06/2025

[View](/mt/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (55.73 KB - PDF)

**First published:**

10/06/2025

[View](/nl/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (58.67 KB - PDF)

**First published:**

10/06/2025

[View](/no/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_no.pdf)

polski (PL) (62.92 KB - PDF)

**First published:**

10/06/2025

[View](/pl/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.23 KB - PDF)

**First published:**

10/06/2025

[View](/pt/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_pt.pdf)

română (RO) (59.56 KB - PDF)

**First published:**

10/06/2025

[View](/ro/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61.9 KB - PDF)

**First published:**

10/06/2025

[View](/sk/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (56.5 KB - PDF)

**First published:**

10/06/2025

[View](/sl/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (53.72 KB - PDF)

**First published:**

10/06/2025

[View](/fi/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (55.71 KB - PDF)

**First published:**

10/06/2025

[View](/sv/documents/all-authorised-presentations/qoyvolma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Qoyvolma Active substance ustekinumab International non-proprietary name (INN) or common name ustekinumab Therapeutic area (MeSH)

- Psoriasis
- Arthritis, Psoriatic
- Colitis, Ulcerative
- Crohn Disease

Anatomical therapeutic chemical (ATC) code L04AC05

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Adult Crohn's Disease Qoyvolma is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist. Paediatric Crohn's Disease Qoyvolma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy. Ulcerative colitis Qoyvolma is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic.

Plaque psoriasis Qoyvolma is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A). Paediatric plaque psoriasis Qoyvolma is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Psoriatic arthritis (PsA) Qoyvolma, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

## Authorisation details

EMA product number EMEA/H/C/006649

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Celltrion Healthcare Hungary Kft.

1062 Budapest

Opinion adopted 27/03/2025 Marketing authorisation issued 02/06/2025 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Qoyvolma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (151.63 KB - PDF)

**First published:** 09/09/2025

[View](/en/documents/procedural-steps-after/qoyvolma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Qoyvolma : EPAR - Public assessment report

Adopted

Reference Number: EMA/130000/2025

English (EN) (6.23 MB - PDF)

**First published:** 10/06/2025

[View](/en/documents/assessment-report/qoyvolma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Qoyvolma

Adopted

Reference Number: EMA/89444/2025

English (EN) (164.43 KB - PDF)

**First published:** 28/03/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-qoyvolma_en.pdf)

#### News on Qoyvolma

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 March 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-march-2025) 28/03/2025

**This page was last updated on** 17/10/2025

## Share this page

[Back to top](#main-content)